Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2004-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-003-0495-3PMID 14999431PMCID PMC11033018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine

  2003cited by this paper
• A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

  2002cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

  2001cited by this paper
• A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection

  2001cited by this paper
• Dendritic Cells Acquire Antigens from Live Cells for Cross-Presentation to CTL1

  2001cited by this paper
• Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

  2001cited by this paper
• Active immunization against cancer with dendritic cells: The near future

  2001cited by this paper
• Role of Tumor Cell Apoptosis in Tumor Antigen Migration to the Draining Lymph Nodes1

  2000cited by this paper
• Immunization of cancer patients with autologous cancer‐derived heat shock protein gp96 preparations: A pilot study

  2000cited by this paper
• Consequences of Cell Death

  2000cited by this paper
• Dendritic cell vaccination for cancer therapy

  2000cited by this paper
• Consequences of cell death: exposure to necrotic tumor cells

  2000cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

  2000cited by this paper
• The dendritic cell and human cancer vaccines.

  2000cited by this paper
• Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

  1999cited by this paper
• Natural adjuvants: Endogenous activators of dendritic cells

  1999cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.

  1999cited by this paper
• Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

  1999cited by this paper
• Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response

  1999cited by this paper
• Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes

  1998cited by this paper
• Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Perspective on allogeneic melanoma lysates in active specific immunotherapy.

  1998cited by this paper
• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

  1998cited by this paper
• Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

  1998cited by this paper
• Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells

  1998cited by this paper
• The selective engulfment of apoptotic bodies by dendritic cells is mediated by the αvβ3 integrin and requires intracellular and extracellular calcium

  1997cited by this paper
• Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.

  1997cited by this paper
• Origin, maturation and antigen presenting function of dendritic cells.

  1997influential reference
• Constitutive macropinocytosis allows TAP‐dependent major histocompatibility compex class I presentation of exogenous soluble antigen by bone marrow‐derived dendritic cells

  1997cited by this paper
• The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium.

  1997cited by this paper
• Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

  1997cited by this paper
• Vaccine therapy for malignant melanoma

  1996cited by this paper
• Expression of B7 costimulator molecules on mouse dendritic cells.

  1995influential reference
• Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells.

  1995cited by this paper
• Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.

  1993cited by this paper
• Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Action a

  1993cited by this paper
• Attempts to optimize active specific immunotherapy for melanoma.

  1991cited by this paper
• Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

  1990cited by this paper

• "How do we forecast tomorrows' transfusion: Non-transfusional hemotherapy".

  2023cites this paper
• Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles

  2023cites this paper
• Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

  2020cites this paper
• Monocytes complexed to platelets differentiate into functionally deficient dendritic cells

  2020cites this paper
• Ex vivo dendritic cell generation-A critical comparison of current approaches.

  2019cites this paper
• Immune Cell Vaccine for Cancer

  2019cites this paper
• Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies

  2019cites this paper
• Leukocytapheresis in nonmobilized donors for cellular therapy protocols: Evaluation of factors affecting collection efficiency of cells

  2019cites this paper
• The Barcelona Hospital Clínic therapeutic apheresis database

  2018cites this paper
• Chapter 5 – Therapy of Melanoma

  2017cites this paper
• Cellular immunotherapy of cancer: an overview and future directions.

  2017cites this paper
• EXOSOME MEDIATED INNATE AND ADAPTIVE IMMUNE STIMULATION FOR TREATMENT OF CANCER

  2017cites this paper
• Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

  2016cites this paper
• Past, present and forecast of transfusion medicine: What has changed and what is expected to change?

  2016cites this paper
• Melanoma versus vitiligo: Clinical aspects and implications for immunotherapy

  2015cites this paper
• Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

  2015cites this paper
• Tumor cell lysates as immunogenic sources for cancer vaccine design

  2014cites this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cites this paper
• Impacto clínico y pronóstico de la PET/TAC-FDG en pacientes con melanoma cutáneo

  2014cites this paper
• Trial watch

  2012cites this paper
• In vitro analysis of T cell responses induced by breast tumor cell lysate pulsed with autologous dendritic cells

  2012cites this paper
• Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide

  2011cites this paper
• Valoración inicial, diagnóstico, estadificación, tratamiento y seguimiento de los pacientes con melanoma maligno primario de la piel. Documento de consenso de la “Xarxa de Centres de Melanoma de Catalunya i Balears”

  2010cites this paper
• Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

  2010cites this paper
• [Initial evaluation, diagnosis, staging, treatment, and follow-up of patients with primary cutaneous malignant melanoma. Consensus statement of the Network of Catalan and Balearic Melanoma Centers].

  2010cites this paper
• Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.

  2009cites this paper
• Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

  2009cites this paper
• Prognostic value of tyrosinase reverse transcriptase PCR analysis in melanoma sentinel lymph nodes: long‐term follow‐up analysis

  2009cites this paper
• Tumour‐mediated disruption of dendritic cell function: Inhibiting the MEK1/2‐p44/42 axis restores IL‐12 production and Th1‐generation

  2008cites this paper
• Deficient TH-1 Responses From TNF-α–matured and α-CD40–matured Dendritic Cells

  2008cites this paper
• Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

  2008influential citation
• Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma‐derived cell lines

  2008cites this paper
• Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture

  2008cites this paper
• Early diagnosis of melanoma: what do we know?

  2007cites this paper
• Thérapie cellulaire en dermatologie

  2007cites this paper
• Terapia celular en dermatología

  2007cites this paper
• Patient-Specific Vaccines Derived from Autologous Tumor Cell Lines as Active Specific Immunotherapy: Results of Exploratory Phase I/II Trials in Patients with Metastatic Melanoma

  2007cites this paper
• Current immunotherapeutic strategies in malignant melanoma.

  2007cites this paper
• T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

  2007cites this paper
• The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization.

  2007cites this paper
• Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.

  2007cites this paper
• Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

  2006cites this paper
• Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

  2006cites this paper
• Quick Generation of Fully Mature Dendritic Cells From Monocytes With OK432, Low-Dose Prostanoid, and Interferon-α as Potent Immune Enhancers

  2006cites this paper
• The treatment of melanoma with an emphasis on immunotherapeutic strategies.

  2006cites this paper
• IMMUNOTHÉRAPIE ANTITUMORALE PAR TRANSFERT DE L'ARN MESSAGER DE L'ANTIGÈNE MELANA/MART-1

  2006cites this paper
• Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

  2006cites this paper
• Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines

  2006cites this paper
• Dendritic cell immunotherapy for the treatment of neoplastic disease.

  2006cites this paper